Shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) have been assigned a consensus broker rating score of 2.50 (Hold) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has issued a buy rating on the company. Aevi Genomic Medicine’s rating score has declined by 25% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.

Brokers have set a one year consensus target price of $5.17 for the company and are expecting that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also assigned Aevi Genomic Medicine an industry rank of 233 out of 265 based on the ratings given to its competitors.

Separately, Jefferies Group reissued a “hold” rating and issued a $1.50 price objective on shares of Aevi Genomic Medicine in a research report on Thursday, September 28th.

In related news, Director Sol J. Barer purchased 421,032 shares of the company’s stock in a transaction that occurred on Tuesday, October 17th. The stock was purchased at an average price of $1.26 per share, with a total value of $530,500.32. Following the completion of the transaction, the director now owns 1,028,032 shares of the company’s stock, valued at approximately $1,295,320.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Garry Arthur Neil purchased 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 17th. The shares were bought at an average cost of $1.26 per share, with a total value of $94,500.00. Following the transaction, the insider now directly owns 114,774 shares of the company’s stock, valued at approximately $144,615.24. The disclosure for this purchase can be found here. In the last three months, insiders bought 615,079 shares of company stock valued at $775,000. Company insiders own 15.20% of the company’s stock.

An institutional investor recently raised its position in Aevi Genomic Medicine stock. Wells Fargo & Company MN raised its stake in shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) by 433.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 130,662 shares of the biotechnology company’s stock after purchasing an additional 106,178 shares during the period. Wells Fargo & Company MN owned 0.35% of Aevi Genomic Medicine worth $165,000 at the end of the most recent reporting period. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Aevi Genomic Medicine (NASDAQ GNMX) traded up $0.01 on Friday, reaching $1.34. 68,926 shares of the company’s stock were exchanged, compared to its average volume of 191,075. The firm has a market capitalization of $78.91, a PE ratio of -1.19 and a beta of 0.40. Aevi Genomic Medicine has a one year low of $0.98 and a one year high of $6.18.

Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). During the same quarter last year, the business earned ($0.29) EPS. sell-side analysts forecast that Aevi Genomic Medicine will post -0.88 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Zacks: Aevi Genomic Medicine, Inc. (GNMX) Given $5.17 Average Price Target by Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease.

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.